Cdk4 Antibodies

Santa Cruz Biotechnology features a diverse variety of Cdk4 monoclonal antibodies for research in cell cycle regulation and cancer biology. Cdk4 Antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Cyclin-dependent kinase 4 (Cdk4) plays a crucial role in the regulation of the cell cycle, particularly in the transition from the G1 phase to the S phase. By phosphorylating the retinoblastoma protein (Rb), Cdk4 facilitates cell cycle progression, making it a key player in cellular proliferation. Dysregulation of Cdk4 activity is often associated with various cancers, highlighting its significance as a therapeutic target and a biomarker for tumor progression. Understanding Cdk4's role in cell cycle regulation provides valuable insights into cancer development and potential treatment strategies. Investigating Cdk4 pathways helps reveal complex cellular mechanisms involved in both normal and abnormal cell division. Research focusing on Cdk4 continues to advance our understanding of cancer biology and therapeutic approaches. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific knowledge in cell cycle regulation and cancer research.